← Back to Search

Anti-metabolites

MRTX1719 for Solid Tumors

Phase 1 & 2
Recruiting
Research Sponsored by Mirati Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must have received standard therapies appropriate for their tumor type and stage with disease progression on or after the most recent treatment
Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue or ctDNA
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a new drug for safety and how well it works in patients with a certain type of cancer.

Who is the study for?
This trial is for adults with advanced solid tumors that can't be surgically removed and have a specific genetic change called MTAP deletion. Participants must have tried standard treatments without success, be in fairly good health, and able to perform daily activities with ease or only slight difficulty.Check my eligibility
What is being tested?
The study tests MRTX1719's safety and effectiveness against various solid tumors with the MTAP deletion. It's an early-stage trial (Phase 1/2), where researchers also look at how the body processes the drug and its impact on tumor size.See study design
What are the potential side effects?
Potential side effects aren't specified here but may include typical reactions to cancer drugs such as nausea, fatigue, risk of infection, blood count changes, or other organ-related issues based on similar trials.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer has worsened despite receiving all standard treatments.
Select...
My cancer has a specific genetic change called MTAP deletion.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My cancer cannot be removed by surgery or has spread to other parts of my body.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase 1/1B: Number of patients who experience a treatment-related adverse event
Phase 1: Number of Patients who Experience Dose-Limiting Toxicity
Phase 2: Duration of response (DOR)
+3 more
Secondary outcome measures
Oral cavity
Oral cavity
Area under the plasma concentration versus time curve (AUC)
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Phase 2Experimental Treatment1 Intervention
MRTX1719 RP2D administered to separate cohorts of patients with selected solid tumor malignancies with MTAP homozygous deletion to include the following: Mesothelioma, Pancreatic Adenocarcinoma, NSCLC, Malignant Peripheral Nerve Sheath Tumor, Other Solid Tumors
Group II: Phase 1/1BExperimental Treatment1 Intervention
Dose Escalation/Evaluation

Find a Location

Who is running the clinical trial?

Mirati Therapeutics Inc.Lead Sponsor
70 Previous Clinical Trials
7,835 Total Patients Enrolled
Ron Schazer, MDStudy DirectorMirati Therapeutics Inc.
Ronald Shazer, MDStudy DirectorMirati Therapeutics Inc.
1 Previous Clinical Trials
200 Total Patients Enrolled

Media Library

MRTX1719 (Anti-metabolites) Clinical Trial Eligibility Overview. Trial Name: NCT05245500 — Phase 1 & 2
Non-Small Cell Lung Cancer Research Study Groups: Phase 1/1B, Phase 2
Non-Small Cell Lung Cancer Clinical Trial 2023: MRTX1719 Highlights & Side Effects. Trial Name: NCT05245500 — Phase 1 & 2
MRTX1719 (Anti-metabolites) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05245500 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In what locations are the experiments for this trial being conducted?

"At present, 6 sites are actively seeking patients for this medical trial. These locations span from Boston to New york, with other centres situated in between. To limit the need to travel extensively, it is recommended that you select a site nearest your home address."

Answered by AI

Is this clinical research enrolling new participants at present?

"Affirmative. Evidence supplied on the clinicaltrials.gov website indicates that this medical experiment was posted on June 2nd 2022 and is currently recruiting patients, seeking 339 participants from 6 different sites."

Answered by AI

How many participants are currently taking part in this research project?

"Affirmative. As per the records on clinicaltrials.gov, this experimental trial is actively enrolling participants from June 2nd 2022 onwards. 339 people are being sought out across 6 sites for involvement in the study and its last update was August 8th 2022."

Answered by AI

Who else is applying?

What site did they apply to?
Mayo Clinic
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion
2022. "Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05245500.
All > Mesothelioma
~193 spots leftby Apr 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top